TSRO TESARO, Inc.

149.11
-4.08  -3%
Previous Close 153.19
Open 152.84
Price To book 16.06
Market Cap 8.03B
Shares 53,864,000
Volume 675,370
Short Ratio 7.63
Av. Daily Volume 973,525

SEC filingsSee all SEC filings

  1. 8-K - Current report 17836664
  2. 8-K - Current report 17828595
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827502
  4. 8-K - Current report 17826353
  5. DEF 14A - Other definitive proxy statements 17747751

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 2H 2017.
Niraparib - AVANOVA
Phase 1/2 enrolling as of February 2017.
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Phase 3 trial to continue enrolling through 2017.
Niraparib - PRIMA
First-line ovarian cancer
CRL January 11 2017. Resubmission noted 2Q 2017. PDUFA date late 2Q 2017.
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 3 trial no longer be expected to serve as a registration trial - noted March 27, 2017.
Niraparib - BRAVO
Cancer - breast
PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.
Niraparib - NOVA (Niraparib Ovarian)
Cancer - ovarian
Phase 2 data due 2H 2017.
Niraparib - (QUADRA trial)
Cancer - ovarian
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients

Latest News

  1. Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  2. National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community
  3. Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments
  4. TESARO, Inc. – Value Analysis (NASDAQ:TSRO) : May 18, 2017
  5. Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug?
  6. TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : May 17, 2017
  7. Edited Transcript of TSRO earnings conference call or presentation 9-May-17 8:15pm GMT
  8. TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer
  9. Tesaro reports 1Q loss
  10. TESARO Announces First-Quarter 2017 Operating Results
  11. Investor Network: TESARO, Inc. to Host Earnings Call
  12. KITE Plunges, Take Sector With It
  13. Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
  14. TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
  15. Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space
  16. TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
  17. TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
  18. TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017
  19. Tesaro Announces Participation in Two Investor Conferences

SEC Filings

  1. 8-K - Current report 17836664
  2. 8-K - Current report 17828595
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827502
  4. 8-K - Current report 17826353
  5. DEF 14A - Other definitive proxy statements 17747751
  6. 8-K - Current report 17730551
  7. CT ORDER - Confidential treatment order 17714324
  8. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 17705757
  9. CT ORDER - Confidential treatment order 17700486
  10. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17648582